Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

430 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial.
Lawal IO, Jani AB, Adediran OA, Goyal S, Abiodun-Ojo OA, Dhere VR, Marcus CV, Joshi SS, Master VA, Patel PR, Goodman M, Shelton JW, Kucuk O, Hershatter B, Fielder B, Halkar RK, Schuster DM. Lawal IO, et al. Among authors: kucuk o. J Nucl Med. 2023 Apr;64(4):586-591. doi: 10.2967/jnumed.122.264832. Epub 2022 Nov 3. J Nucl Med. 2023. PMID: 36328489 Free PMC article.
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah's witness: A case report.
Zhuang TZ, Harik L, Force S, Hadadi A, Bilen MA, Brown JT, Carthon BC, Goldman J, Kucuk O, Master VA, Nazha B. Zhuang TZ, et al. Among authors: kucuk o. Front Oncol. 2022 Dec 2;12:949400. doi: 10.3389/fonc.2022.949400. eCollection 2022. Front Oncol. 2022. PMID: 36530969 Free PMC article.
Impact of 18 F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy.
Lawal IO, Marcus C, Schuster DM, Goyal S, Adediran OA, Dhere VR, Joshi SS, Abiodun-Ojo OA, Master VA, Patel PR, Fielder B, Goodman M, Shelton JW, Kucuk O, Hershatter B, Halkar RK, Jani AB. Lawal IO, et al. Among authors: kucuk o. Clin Nucl Med. 2023 Apr 1;48(4):e153-e159. doi: 10.1097/RLU.0000000000004590. Epub 2023 Feb 8. Clin Nucl Med. 2023. PMID: 36754362 Free PMC article.
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE, Shabto JM, Goyal S, Liu Y, Martini DJ, Nazha B, Brown JT, Yantorni LB, Anne Russler G, Caulfield S, Joshi SS, Narayan VM, Kissick H, Ogan K, Master VA, Carthon BC, Kucuk O, Bilen MA. Sanda GE, et al. Among authors: kucuk o. Oncologist. 2023 Dec 11;28(12):1072-1078. doi: 10.1093/oncolo/oyad154. Oncologist. 2023. PMID: 37285524 Free PMC article.
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B, Zhuang T, Wu S, Brown JT, Magee D, Carthon BC, Kucuk O, Nabhan C, Barata PC, Heath EI, Ryan CJ, McKay RR, Master VA, Bilen MA. Nazha B, et al. Among authors: kucuk o. Cancer. 2023 Dec 15;129(24):3884-3893. doi: 10.1002/cncr.34982. Epub 2023 Aug 11. Cancer. 2023. PMID: 37565840 Free article.
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.
Coen JJ, Rodgers JP, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou J, Jani AB, Kucuk O, Souhami L, Pugh SL, Sandler HM, Shipley WU. Coen JJ, et al. Among authors: kucuk o. Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):153-161. doi: 10.1016/j.ijrobp.2024.08.007. Epub 2024 Aug 13. Int J Radiat Oncol Biol Phys. 2025. PMID: 39147209 Clinical Trial.
The diagnostic challenges of differentiating metastatic extramammary Paget disease and prostatic adenocarcinoma: A case report and review of the literature.
Palmateer G, Nicaise EH, Gandhi J, Goodstein T, Sheng M, Ogan K, Kucuk O, Yushak M, Sanda MG, Delman KA, Master V. Palmateer G, et al. Among authors: kucuk o. Urol Case Rep. 2024 Oct 24;57:102875. doi: 10.1016/j.eucr.2024.102875. eCollection 2024 Nov. Urol Case Rep. 2024. PMID: 39553440 Free PMC article.
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
Bilen MA, Vo BT, Liu Y, Greenwald R, Davarpanah AH, McGuire D, Shiradkar R, Li L, Nazha B, Brown JT, Williams S, Session W, Russler G, Caulfield S, Joshi SS, Narayan VM, Filson CP, Ogan K, Kucuk O, Carthon BC, Del Balzo L, Cohen A, Boyanton A, Prokhnevska N, Cardenas MA, Sobierajska E, Jansen CS, Patil DH, Nicaise E, Osunkoya AO, Kissick H, Master VA. Bilen MA, et al. Among authors: kucuk o. Res Sq [Preprint]. 2024 Aug 8:rs.3.rs-4849400. doi: 10.21203/rs.3.rs-4849400/v1. Res Sq. 2024. PMID: 39149474 Free PMC article. Preprint.
430 results